All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
A Phase 1 Open-label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRa) Antibody Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
A Phase 1/2 dose escalation and dose expansion study of BA3011 alone and in combination with Nivolumab in adult and adolescent patients 12 years and older with advanced solid tumors
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (Dragon)
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (Medi4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (Medi4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
GOG-3059 - A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
combined with PAC in subjects with platinum-resistant, recurrent ovarian cancer.
A Phase 0 Trial of HB-201 for Subjects with Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or with Locally Advanced Cervical Cancer Treated with Chemotherapy and Radiation
profiles in subjects with HPV 16+ head and neck cancer (HNC) and cervical cancer. To compare the immunologic response of HB-201 when it is administered as an IV or IT injection.
A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma Who Have Progressed on Prior Chemotherapy
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
A Multicenter Phase II Trial of Paclitaxel with and without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.